GENELUX Corp
Business
Genelux is a late-stage biopharmaceutical company developing oncolytic viral immunotherapies using modified vaccinia virus (VACV) to treat aggressive and difficult-to-treat cancers. Its lead candidate, Olvi-Vec, is in Phase 3 registrational trials for platinum-resistant ovarian cancer and Phase 2 trials for recurrent lung cancers (NSCLC and SCLC), administered via intraperitoneal and intravenous delivery. The company operates its own cGMP manufacturing facility in San Diego and licenses rights to its VACV platform in China through an exclusive agreement with Newsoara.
Summary from 10-K filed 2026-03-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Revenue | 8,000 | 8,000 | 170,000 | 11 | |
| Research and development | 20 | 19 | 13 | 9 | |
| General and administrative | 13 | 13 | 12 | 5 | |
| Total operating expenses | 33 | 32 | 24 | 14 | |
| Operating loss | −33 | −32 | −24 | −3 | |
| Interest income | 711,000 | 700,000 | 182,000 | — | |
| Bond accretion income | 358,000 | 757,000 | 62,000 | — | |
| Gain on extinguishment of accounts payable | — | 370,000 | — | — | |
| Total other income | 1 | 2 | −4 | −1 | |
| Net loss | −32 | −30 | −28 | −5 | |
| Net loss per common share - basic | −0.86 | −0.95 | −1.16 | −0.57 | |
| Net loss per common share - Diluted | −0.86 | −0.95 | −1.16 | −0.57 | |
| Weighted Average Number of Shares Outstanding, Basic | 37 | 31 | 31 | 9 | |
| Weighted Average Number of Shares Outstanding, Diluted | 37 | 31 | 24 | 9 | |
| Unrealized (loss) gain on available-for-sale securities | −55,000 | 50,000 | — | — | |
| Comprehensive loss | −32 | −30 | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash, cash equivalents and restricted cash | 5 | 9 | 9 | 397,000 | — | |
| Marketable securities | 9 | 22 | — | — | — | |
| Prepaid expenses and other current assets | 535,000 | 653,000 | 1 | 1 | — | |
| Total current assets | 15 | 32 | 24 | 2 | — | |
| Property and equipment, net | 2 | 1 | 1 | 644,000 | — | |
| Right of use assets | 2 | 2 | 2 | 1 | — | |
| Other assets | 144,000 | 92,000 | 92,000 | 92,000 | — | |
| Total Assets | 19 | 35 | 28 | 6 | — | |
| Accounts payable and accrued expenses | 4 | 6 | 4 | 7 | — | |
| Accrued payroll and payroll taxes | 1 | 1 | 2 | 3 | — | |
| Lease liabilities, current portion | 427,000 | 329,000 | 653,000 | 266,000 | — | |
| Total current liabilities | 6 | 7 | 7 | 32 | — | |
| Lease liabilities, net of current portion | 1 | 2 | 2 | 1 | — | |
| Total liabilities | 7 | 8 | 8 | 41 | — | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Common stock, par value $0.001, 200,000,000 shares authorized; 38,139,144 and 34,728,140 shares issued and outstanding | 38,000 | 35,000 | 27,000 | 9,000 | — | |
| Treasury stock, 433,333 shares, at cost | −433,000 | −433,000 | −433,000 | −433,000 | — | |
| Additional paid-in capital | 295 | 278 | 241 | 154 | — | |
| Accumulated other comprehensive income | 9,000 | 64,000 | 14,000 | 2,000 | — | |
| Accumulated deficit | −284 | −251 | −222 | −190 | — | |
| Total stockholders equity | 12 | 26 | 19 | −36 | −33 | |
| Total Liabilities and Stockholders Equity | 19 | 35 | 28 | 6 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Depreciation expense | 200,000 | 200,000 | 499,000 | 553,000 | |
| Accretion of discount on marketable securities | −226,000 | −757,000 | — | — | |
| Right-of-use asset | 330,000 | 668,000 | 519,000 | 415,000 | |
| Stock compensation | 6 | 6 | 3 | 2 | |
| Fair value of restricted stock units | 898,000 | 2 | 940,000 | — | |
| Cost of stock option modifications and repricing | 806,000 | 332,000 | 3 | — | |
| Prepaid expenses and other assets | 66,000 | 359,000 | 483,000 | −168,000 | |
| Accounts payable and accrued expenses | −1 | 2 | −2 | 2 | |
| Accrued payroll and payroll taxes | 438,000 | −1 | −735,000 | — | |
| Lease liability | −337,000 | −651,000 | −523,000 | −389,000 | |
| Net cash used in operating activities | −25 | −21 | −20 | −4 | |
| Purchases of property and equipment | −1 | −381,000 | −1 | −49,000 | |
| Purchase of marketable securities | −18 | −29 | −14 | — | |
| Proceeds from sales and maturities of marketable securities | 32 | 21 | — | — | |
| Net cash provided by (used in) investing activities | 12 | −8 | −15 | −49,000 | |
| Proceeds from common stock issued | 10 | 28 | 25 | — | |
| Proceeds from common stock issued in connection with the Companys equity award programs | 104,000 | 125,000 | — | — | |
| Proceeds from the exercise of stock options | 14,000 | — | 1 | — | |
| Proceeds from the exercise of stock warrants | 224,000 | 688,000 | 3 | 120,000 | |
| Net cash provided by financing activities | 10 | 29 | 44 | −478,000 | |
| Net decrease in cash, cash equivalents and restricted cash | −3 | −853,000 | 9 | −4 | |
| Unrealized (loss) gain on marketable securities | −55,000 | 50,000 | — | — | |
| Initial recognition of right-of-use asset obtained in exchange for operating lease liabilities | 153,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is GENELUX Corp's CIK number?
GENELUX Corp's SEC CIK number is 0001231457 (1231457). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find GENELUX Corp's SEC filings?
All of GENELUX Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did GENELUX Corp last report earnings?
GENELUX Corp (GNLX) most recently filed an earnings 8-K with the SEC on Mar 25, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001641172-25-000528). This is GENELUX Corp's most recent earnings filing of record — not a forecast of its next earnings date.
What is GENELUX Corp's most recent earnings 8-K?
GENELUX Corp's latest earnings 8-K (Item 2.02) was filed Mar 25, 2025 under accession 0001641172-25-000528. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View GENELUX Corp's latest earnings 8-K →
Look up any company's CIK number →